Abstract
Objective: To evaluate medication adherence, pharmacokinetics and exposure versus response relationships in patients with myelodysplastic syndromes (MDS). Methods: Ninety adult patients with MDS received oral topotecan (1.2 mg/m2) either once a day for 10 days or twice a day for 5 days every 21 days for up to six cycles. Dosing histories were collected using electronic monitoring devices fitted to medication vials. Topotecan plasma concentrations were measured, and exposure was determined by a sparse sampling approach and Bayesian estimation methods. Relationships between exposure and clinical response and toxicity were evaluated using logistic regression. Results: Overall adherence was excellent with 90% of patients taking the prescribed number of doses in cycle 1. Adherence did not differ between the two regimens. Topotecan pharmacokinetics were described using a one compartment open model with first order absorption and elimination. Pharmacokinetic parameter estimates did not differ between the once a day and twice a day dosing groups. While topotecan exposure was greater in the twice a day arm compared to the once a day arm due to drug accumulation, exposure did not correlate with clinical response. However, the probability of needing a platelet transfusion in the twice a day arm was significantly increased (by 35%) as a result of greater steady-state plasma topotecan concentrations. Conclusions: Adherence is high in patients with MDS receiving oral topotecan, whether the drug is prescribed once or twice daily. The optimal schedule cannot be determined from this study, as there was no evident relationship between any pharmacokinetic parameter and clinical response.
Similar content being viewed by others
References
Fenaux P (1999) Myelodysplastic syndromes. In: Degos L, Linch DC, Lowenberg B (eds) Textbook of malignant haematology. Martin Dunitz, London
Burns CP (1999) Myelodysplastic syndromes. In: Foley JF, Vose JM, Armitage JO (eds) Current therapy in cancer. Saunders, Philadelphia, pp 374–381
Beran M, Estey E, OBrien S, Cortes J, Koller CA, Giles FJ et al (1999) Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17:2819–2830
Beran M, Kantarjian H, OBrien S, Koller C, Al-Bitar M, Arbuck S et al (1996) Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 88:2473–2479
Beran M, Shen Y, Kantarjian H, O’Brien S, Koller CA, Giles FJ et al (2001) High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate adjusted comparison of five regimens. Cancer 92:1999–2015
DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16:2557–2567
Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL et al (1998) Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a cancer and leukemia Group B study. J Clin Oncol 16:3302–3309
Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME et al (1998) Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res 4:1153–1158
Cramer J, Spilker B (1991) Patient compliance in medical practice and clinical trials. Raven Press, New York
Kastrissios H, Blaschke TF (1997) Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol 37:451–475
Beal SL, Sheiner LB (1992) NONMEM Users Guide, NONMEM Project Group. UCSF, San Francisco
Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic–pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20:511–528
National Cancer Institute (1998) Guidelines for reporting of adverse drug reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda
Lee C, Nicholson P, Souhami R, Deshmukh A (1992) Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 10:1007–1013
Waterhouse D, Calzone K, Mele C, Brenner D (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11:1189–1197
Ennis K, Reichard R (1997) Maximizing drug compliance in the elderly. Postgrad Med 102:211–224
Herben V, Rosing H, tenBokkel Huinink W, van Zomeren D, Batchelor D, Doyle E et al (1999) Oral topotecan: bioavailability and the effect of food co-administration. Br J Cancer 80:1380–1386
Loos WJ, Gelderblom HJ, Sparreboom A, Verweij J, de Jonge MJ (2000) Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. Clin Cancer Res 6:2685–2689
Creemers G, Gerrits C, Eckhardt J, Schellens J, Burris H, Planting A et al (1997) Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 15:1087–1093
Gerrits C, Burris H, Schellens J, Planting A, van den Burg M, Rodriguez G et al (1998) Five days of oral topotecan (Hycamtin) a phase I and pharmacological study in adult patients with solid tumors. Eur J Cancer 34:1030–1035
Gerrits CJ, Schellens JH, Burris H, Eckhardt JR, Planting AS, van der Burg ME et al (1999) A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 5:69–75
Schellens J, Creemers G, Beijen J, de Boer-Dennert M, McDonald M, Davies B, Verweij J (1996) Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 73:1268–1271
White SC, Cheesman S, Thatcher N, Anderson H, Carrington B, Hearn S et al (2000) Phase II study of oral topotecan in advanced non-small cell lung cancer. Clin Cancer Res 6:868–873
Montazeri A, Boucaud M, Lokiec F, Pinguet F, Culine S, Deporte-Fety R et al (2000) Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemother Pharmacol 46:375–381
O’Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS et al (1996) Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 14:3062–3073
Léger F, Loos WJ, Fourcade J, Bugat R, Goffinet M, Mathijssen RHJ, Verweij J, Sparreboom A, Chatelut E (2004) Factors affecting pharmacokinetic variability of oral topotecan: a population analysis. Br J Cancer 90:343–347
Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL et al (1992) Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706–713
Loos WJ, Gelderblom HJ, Verweij J, Brouwer E, de Jonge MJ, Sparreboom A (2000) Gender-dependent pharmacokinetics of topotecan in adult patients. Anticancer Drugs 11:673–680
Jonsson E, Fridborg H, Csoka K, Dhar S, Sundstrom C, Nygren P, Larsson R (1997) Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 76:211–219
Erickson-Miller CL, May RD, Tomaszewski J, Osborn B, Murphy MJ, Page JG, Parchment RE (1997) Different toxicity of camptothecin, topotecan, and 9-aminocamptothecin to human, canine and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol 39:467–472
Acknowledgments
This study was funded, in part, by NCI grant CA44691.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Klein, C.E., Kastrissios, H., Miller, A.A. et al. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 57, 199–206 (2006). https://doi.org/10.1007/s00280-005-0023-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-005-0023-6